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Abstract
Background: In Europe, scant information is available about prescription practices for pain medications. The aim of
this research was to assess changes in prescription rates of non-opioid, weak opioid, and strong opioid medications
between 2006 and 2013 in the Swiss population.
Methods: Using insurance claims data covering one-sixth of the Swiss population, we analyzed the numbers of
reimbursed pain medications, the number of reimbursements per persons, and the cumulative dose in milligrams.
For opioids, the morphine equivalent dose and treatment days were calculated. Data were extrapolated to the dose
per day per 100’000 population stratified by age, gender, and canton.
Results: In total, 4’746’942 paracetamol, 2’156’620 NSAIDs or Coxibs, 931’129 metamizole, 1’322’272 weak opioid,
and 807’835 strong opioid claims were analyzed. Between 2006 and 2013, the increase in claims per 100’000
persons was 32% for paracetamol, 242% for metamizole, 107% for NSAIDS, 86% for Coxibs, 13% for weak opioids,
and 121% for strong opioids. For strong opioids the total MED in mg /100’000 increased by 117%, the treatment
days /100’000 by 101%. For strong opioids, fentanyl was most frequently used (increase between 2006 and 2013
by 91% for MED/100’000 persons and 94% treatment days / 100’000) followed by buprenorphine and oxycodone.
The highest proportional increase in MED / 100’000 was observed for methadone (+1414%) and oxycodone
(+313%). Marked geographical variation was detected in the use of metamizole, paracetamole, and strong opioids
in different cantons.
Conclusion: The analysis of insurance claims data provides evidence that the prescription rates for pain medications
increased in Switzerland within the last ten years, in particular for metamizole and strong opioids. Furthermore, the
prescription rates for metamizole, paracetamol, and strong opioids varied substantially between different cantons in
Switzerland.
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Background
Between 1990 and 2010, the number of patients with
non-infectious illnesses increased worldwide by more
than 40% [1]. As a consequence, the number of patients
with chronic pain conditions increased, and the main
causes are musculoskeletal disorders, the sequela of
injuries, and malignancies [1, 2]. In the 1990s, the World
Health Organization (WHO) recommended a stepwise
increase of treatment intensity in cancer pain which im-
proved pain control (the WHO pain relief ladder [3, 4]).
For mild pain, non-opioids were recommended; for mild
to moderate pain, weak opioids (e.g. tramadol, codeine);
and for strong pain, strong opioids (e.g. morphine, fentanyl)
[4]. Although the stepwise approach is widely accepted, the
choice of a specific pain medication is influenced by several
factors including comorbidities. Further, the withdrawal of
most cox-2 inhibitors from the market reduced the
non-opioid based treatment options [5].
Opioids are well established for the relief of acute
strong pain, chronic pain in patients with active cancer,
or for symptom relief at the end of life. In chronic non-
cancer pain, opioids are considered second line drugs
because they are usually not more effective than non-
opioid pain medications [6, 7] but potentially decrease
quality of life and pain control [8, 9]. Despite these
limitations, opioids are increasingly prescribed for chronic
non-cancer pain and the prescription rates have reached
enormous dimensions in some countries [10–12]. Accord-
ing to consumer data, the sale of opioids increased in the
US from 96 mg of morphine equivalents per person in
1997 to 710 mg per person in 2010 [6]. The total amount
is equivalent to 7.1 kg of opioid medication per 10,000
people, or 5 mg of hydrocodone every 6 h for 45 days for
every adult American [6]. In parallel to the increased use
of opioids, the risk for unintentional opioid overdose of
strong opioids increased [13–16] and resulted in higher
hospital admission rates [17]. In Europe, scant information
is available about prescription practice for pain medica-
tions. However, a study on changes in pain medication use
in Scotland showed an increased use of pain medications
and an 18-fold increase in the use of strong opioids indi-
cating that also in Europe strong opioids are increasingly
used [18].
The aim of this analysis was to describe changes in
prescription rates of non-opioid, weak opioid, and strong
opioid medications between 2006 and 2013 in age groups
and geographical areas in the Swiss population. We hypoth-
esized that the prescription of strong opioids increased
exponentially compared to other pain medications.
Methods
Study design
Analysis was done of insurance claims data from one of
the major health insurers in Switzerland, the Helsana
health insurance group. The insurer covers 1.2 million
individuals (approximately one-sixth of the Swiss popu-
lation) in all 26 cantons, and maintains records of all
health care invoices including information about pre-
scribed medications. The patient-level linked database
provides information on socio-demographic data, health
insurance status, prescribed drugs, health care utilization
and its associated costs (inpatient, outpatient) as well as
the date of death.
Study population
All administrative claims data of adults (age 18 years
and older) who received reimbursement for at least one
pain prescription between January 2006 and December
2013 were included in this analysis. All reimbursed
medication claims are labeled with a unique code for the
pharmaceutical class (see definitions). The code is based
on the WHO pharmacological Anatomical Therapeutic
Chemical (ATC) classification system [19]. Patients were
identified by the ATC codes representing the following
pain medications that were included in this analysis:
non-opioids, weak opioids, and strong opioids.
Swiss healthcare system and regulation for opioid
prescription
In Switzerland compulsory basic health insurance is univer-
sal and covers the population of 8.2 million persons. There
are virtually no uninsured residents. The basic health insur-
ance covers a comprehensive benefits package defined by
federal authorities and can be supplemented by private/
semiprivate insurances that offer additional services [20].
The coverage provided through compulsory, individually
purchased health insurance is a comprehensive benefit
package that leads to out-of-pocket spending from copay-
ments and deductibles [20]. The amount of copayment
depends on the chosen deductible class. Several health care
providers and payers are on the market and no centralized
registration of prescriptions is available. Further, the 26
Swiss cantons are responsible for the planning and delivery
of the health services and thus, the health care system is
highly decentralized. Therefore, no centralized opioid use
register is available. Opioids cannot be purchased over the
counter and for strong opioids a special prescription (a so
called “prescription for narcotic substances”) is issued on
prescriptions with 3 copies including a unique identification
number. One copy remains with the prescribing physician,
one with the pharmacy and with the insurance company.
While this regulation reduces the risk of abuse, there is no
central database that would identify patients with multiple
prescriber or other misuse.
Definitions
Non-opioid pain medications: paracetamol (N02BE01,
N02BE51, N02BE71), nonsteroidal anti-inflammatory drugs
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(NSAIDs, M01AA, M01AB, M01AC, M01AE, M01AG),
cox-inhibitors (Coxibs, M01AH), metamizole (N02BB02,
N02BB52, N02BB72).
Weak opioids included oral or rectal opioid formulations
with a morphine conversion factor of 0.3 or less. ATC
codes and substances for weak opioids were: N02AA59 (co-
deine and combinations), N02AX01 (tilidine), N02AX02
(tramadol), N02AX06 (tapentadol).
Strong opioids: all opioids not defined as weak. The
full list of ATC codes, opioid substances, conversion fac-
tors, route of administration, and defined daily dose are
provided in Additional file 1. In Switzerland hydroco-
done (ATC code R05DA03) is not listed by the author-
ities and not covered by the basic insurance coverage
and therefore, not included in this analysis. However,
hydrocodone is in rare cases prescribed by physicians
and a prescription for narcotic substances is required
with the same regulation as described above.
Reimbursed pain medications: Each reimbursement of
a pain medication (referred to hereafter as a “claim”)
was converted to a total amount of substance by calcu-
lating the number of pills per reimbursement × strength
of the substance. For each pharmaceutical class of pain
medications, the total numbers of claims reimbursed,
the average number of claims per person receiving pain
medications, and the cumulative dose of milligrams (mg)
of the active pharmaceutical substance were calculated
and reported for each year between 2006 and 2013.
Wherever available we calculate the cumulative dose per
drug class: paracetamol, metamizole, weak opioids,
strong opioids. For NSAIDs and Coxibs no dose conver-
sion for individual formulations is available. Therefore,
we report the cumulative dose per substance (e.g.
diclofenac, ibuprofen) and depict selected substances.
Morphine equivalent dose (MED): To account for the
different potencies of opioids, the morphine equivalent
dose (MED) was calculated for each opioid (weak and
strong) as follows: Strength of opioid drug in mg per
unit x quantity of units per reimbursed package x num-
ber of packages x conversion factor for morphine equiv-
alents. The equianalgesic dose conversions are only
estimates and cannot account for individual variability in
genetics and pharmacokinetics. Wherever available we
used conversion factors provided by the Swiss Agency
for Therapeutic Products (Swissmedic, agency compar-
able to the US Food and Drug Administration, FDA) or
the morphine equivalent conversion factor per mg of
opioid was based on the CONSORT classification (CON-
sortium to Study Opioid Risks and Trends [21]). Further,
we consulted the literature relevant to the topic and a
clinical pharmacologist (See Additional file 1: opioids,
examples of brand names, the morphine equivalent
conversion factors, and the route of administration). The
MED calculation for fentanyl patches is based on the
assumption that one patch delivers the dispensed (and
bioavailable) mcg per hour over 72 h. The calculation of
the total bioavailable MED dose in mg equals (mcg/hour
(according to the package reimbursed) x 72 h’ x number
of patches per package x number of packages reimbursed
x 100 [fentanyl conversion factor])/1000. For example, the
total MED in mg for one package containing 10 fentanyl
patches that each delivers 12mcg per hour is calculated as
follows: 12mcg x 72 h × 10 patches × 100 = 864,000mcg/
1000 = 864 mg. For transdermal buprenorphine patches
the assumption is that one patch delivers the dispensed
(and bioavailable) mcg per hour over 96 h. The total MED
dose in milligram equals (mcg/h according to the package
reimbursed x 96 h’ x number of patches per package x
number of packages reimbursed x 95 [buprenorphine
conversion factor]) / 1000.
Defined daily dose (DDD): For strong opioids, treatment
days were calculated by using the defined daily dose
(DDD). The DDD is provided by the WHO ATC and is
based on the assumed average maintenance dose per day
for a drug used for its main indication in adults [19]. The
WHO ATC/ DDD system allows standardization of drug
groupings and a stable drug utilization metric to enable
comparisons of drug use between countries [19].
Treatment days in MED: For strong opioids we calcu-
lated in addition to total MED the treatment days as fol-
lows: total MED per substance/DDD.
Morphine equivalent (MED) per treatment day: Total
MED in mg/Total treatment days (for strong opioids).
Pain medication per 100’000 population: Reimbursed
pain medications were extrapolated to calculate the
amount of each pharmaceutical substance prescribed
and the treatment days per 100’000 population.
Opioid substitution programs: Opioid substitution
programs: We excluded patients using opioids within a
drug substitution program. Since 1999, the insurance
companies reimburse the opioids for drug substitution.
We excluded diamorphine using the corresponding
ATC-code (N07BC06 Diaphin®). Other opioids including
morphine (N02AA01 Sevre-Long®), buprenorphine
(N07BC01 Subutex®, N02AE01 Temgesic®), and methadone
(N07BC02) are used within substitution programs and for
pain treatment. For opioid dependency substitution a
unique outpatient code is used (Tarmed Position 00.0155:
non-physician medication distribution for opioid depend-
ency substitution). We excluded all opioid claims from the
analysis for all patients where this unique outpatient code
was used at least once during the study period (e.g. in a pa-
tient the unique code was identified in the database in 2009
then all opioids reimbursed for this person were excluded).
Statistical methods
Descriptive statistics included median and interquartile
range for the continuous parameters, and percentages
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for the categorical outcomes. The annual number of
claims and the cumulative dose of milligrams of the active
pharmaceutical substance were extrapolated to calculate
the amount of each pharmaceutical substance prescribed
and the treatment days per 100’000 population stratified
by age (strata of 5 years), gender, and canton using
methods proposed for the analysis of complex survey ana-
lysis [22]. The age-dependent use of pain medications was
studied by calculating the mean annual dose per patient
between 2006 and 2013 in the following predefined age
groups: 45 years or younger (reference category), 46 to 65,
66 to 75, 76 to 85, and 86 years and older.
Statistical analysis was performed using the computing
environment R, a freely available system for statistical
computation and graphics environment (https://www.r-
project.org/) [23]. The following software packages were
used: DescTools, mvtnorm, foreign, Rcpp, RDCOMClient,
and tcltk.
Results
In 2013, 43% of the total population covered by a Helsana
health insurance plan were reimbursed for at least one
claim of non-opioid medication, 4.8% for at least one weak
opioid claim, and 2.8% for at least one strong opioid claim.
In total, 4’746’942 paracetamols, 2’156’620 NSAIDs or
Coxibs, 931’129 metamizole, 1’322’272 weak opioids, and
808’751 strong opioid claims were analyzed. Patients re-
ceiving NSAIDs and paracetamol were, on average, youn-
ger (median age 38 and 39 years) than patients receiving
metamizole and opioids (median age 54 and 64 years,
Table 1). On average, more pain medication claims were
reimbursed for women and their average age was higher
than the male subjects. Compared to younger patients (up
to age 45) there was an 8-fold increase in the use of para-
cetamol, and 5.4-fold increase in metamizole use in
patients 85 years and older (Fig. 1). The use of NSAIDs
increased in all age groups including patients over 85
(diclofenac increased 3.6-fold, ibuprofen 4.5, and mefe-
namic acid had a 2.5-fold increase). The use in strong
opioids did not increase and there was only a slight in-
crease in weak opioids in older age groups compared to
the reference group.
Change in claims for non-opioid pain medications
Between 2006 and 2013, the use of non-opioid pain
medications increased between 25% and 237% and the
claims per person rose by 12% (from 2.94 to 3.3, see
Table 2 and for more details Additional file 2). The
extrapolated claims per 100’000 persons showed an in-
crease for paracetamol, metamizole, NSAIDs and Coxibs
by between 32 and 242% (Table 2) with the most substan-
tial increase observed for metamizole (+242%). Compared
to NSAIDS Coxibs were less frequently used (in 2013
NSAIDs 28’932 claims/100’000 persons, Coxibs 3’063
claims/100’000 persons).
Change in claims for weak opioid pain medications
Between 2006 and 2013, the use of weak opioids per
100’000 persons in morphine equivalent dose (MED) in-
creased by 24% although the observed rate of claims per
person did not increase (Table 2). This increase was
mainly due to an increase in tramadol claims (+23%).
Change in claims for strong opioid pain medications
Between 2006 and 2013, the total number of claims for
strong opioids doubled from 64’839 to 137’458 (Table 2).
Table 1 Baseline characteristics for all claims reimbursed between January 2006 and December 2013
NSAID/Coxibs Paracetamol Metamizole Weak Opioids Strong Opioids
Number of claims: n total 2'156'620 4'746'942 931'129 1'322'272 807'835
Number of persons: n 693'928 1'098'925 292'403 268'143 121'455
Morphine equivalent: median (IQR)a - - - 180 (531) 300 (2680.1)
Male: n (%) 293'011 (42.2) 484'176 (44.1) 120'609 (41.2) 111'888 (41.7) 50'329 (41.4)
Female: n (%) 400'917 (57.8) 614'749 (55.9) 171'794 (58.8) 156'255 (58.3) 71'126 (58.6)
Age: median (IQR) 39 (41) 38 (45) 54 (35) 57 (31) 64 (30)
Age male: median (IQR) 36 (43) 36 (47) 52 (33) 55 (29) 61 (29)
Age female: median (IQR) 41 (40) 40 (43) 55 (37) 59 (32) 67 (31)
German partb: n persons (%) 464'237 (66.9%) 766'415 (69.7%) 257'420 (88.0%) 195'149 (72.8%) 101'664 (83.7%)
French partb: n persons (%) 195'934 (28.2%) 259'895 (23.6%) 22'835 (7.8%) 57'929 (21.6%) 15'642 (12.9%)
Italian partb: n persons (%) 33'757 (4.9%) 72'615 (6.6%) 12'148 (4.2%) 15'065 (5.6%) 4'149 (3.4%)
German partb: n claims (%) 1'416'848 (65.7%) 3'059'364 (64.4%) 845'951 (90.9%) 962'477 (72.8%) 671'079 (83.1%)
French partb: n claims (%) 637'028 (29.5%) 1'320'874 (27.8%) 54'124 (5.8%) 286'570 (21.7%) 109'364 (13.5%)
Italian partb: n claims (%) 102'744 (4.8%) 366'704 (7.7%) 31'054 (3.3%) 73'225 (5.5%) 27'392 (3.4%)
amorphine equivalents in milligram
bnumbers calculated based on the area of residency (canton)
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The average claims per person with strong opioids claims
increased from 3.87 to 4.82 (+25%). The median age of
the population receiving strong opioid prescriptions in-
creased between 2006 and 2013 from 66 to 69 years.
Extrapolated to 100’000 persons, the total morphine
equivalent dose (MED) increased by 117% and the total
treatment days by 101%. Fentanyl was the most frequently
prescribed strong opioid in total MED and treatment days
per 100’000 (Additional file 3). The proportions of the dif-
ferent strong opioids in 2013 were as follows: fentanyl
accounted for 29% of the MED per 100’000 persons,
followed by buprenorphine (25%), oxycodone (21%), mor-
phine (19%), hydromorphone (3%), and methadone (3%).
Between 2006 and 2013, the treatment days for fentanyl
increased by 94% and the total MED by 91% (Table 2, see
for more details Additional file 2). The highest propor-
tional increase was observed for methadone (1141%
increase in MED/100’000, 1413% increase in treatment
days/100’000), which was rarely used in 2006, followed by
oxycodone (increased by 313% in MED/100’000 and treat-
ment days/100’000). The use of short-acting formulations
increased for oral use by 509%, and for sublingual use by
301%. Most frequently a transdermal route of application
of opioids was used.
Differences in the use of pain medications in different
Swiss cantons
We found considerable differences in the use of pain
medications across the Swiss cantons (Fig. 2). The most
pronounced differences between Swiss cantons were
identified in the use of metamizole (Fig. 3). In 2013, it
was less used in the French and Italian speaking parts of
Switzerland and mainly used in the German speaking
areas. Paracetamol and weak opioids were more fre-
quently used in the French speaking part. In 2013,
strong opioids were most often used in the cantons of
Jura, Basel-Stadt, Nidwalden, and Glarus (see Fig. 3, for
a comparison of the use of strong opioids in 2006,
depicted in Additional file 4). Between 2006 and 2013,
the most pronounced increases in the use of strong opi-
oids were detected in the cantons of Jura (+260%),
Fribourg (+270%), Basel-Stadt (+219%), Uri (+220%),
and Schaffhausen (+201%). as shown in Fig. 3 and Add-
itional file 4. The increases in strong opioid use were
lowest in the cantons of Nidwalden (+44%), Valais
(+48%), and Zug (+49%).
Discussion
Between 2006 and 2013, we found an increase in claims
per 100’000 persons in almost all pain medications. The in-
crease was most pronounced for metamizole (+324%),
NSAIDS (+124%), Coxibs (+101%), and strong opioids
(+70%). While fentanyl was the most frequently used strong
opioid, we observed the highest proportional increase for
methadone (+1414%), followed by oxycodone (+313%). The
use of short-acting forms including the oral and sublingual
formulation of strong opioids increased markedly. In
patients 85 years of age and older, we found an increased
prescription of all pain medications including NSAIDs.
We found pronounced geographical differences in the
prescriptions for metamizole, paracetamol, and strong
opioids. Metamizole was mainly and increasingly pre-
scribed in the German speaking part of Switzerland.
Paracetamol and weak opioids were more frequently
used in the French speaking part. The prescription for
strong opioids increased between 2006 and 2013, most
Fig. 1 Comparison of the mean annual dose in age groups 45 years and older to patients under the age of 45 years. The mean annual dose increase
compared to the reference group of patients age younger than 45 years (1 = 100%). The mean annual dose of each pharmaceutical group was calculated
by the mean annual dose per patient in the corresponding age group. The mean annual dose was divided by the mean annual dose in the reference
group. ATC codes used: paracetamol (N02BE01, N02BE51, N02BE71), selected NSAIDs (M01AE01 +M01AE51 ibuprofen, M01AB05 +M01AB diclofenac,
M01AG01 mefenamic acid), metamizole (N02BB02, N02BB52, N02BB72). Weak opioids (N02AA59, N02AX0, N02AX02, N02AX06), and strong opioids
(N02AA01-5, N02AA55, N02AB02, NA02AB03, N02AE01, N02AF02, N07BC1-2)
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Table 2 Change in claims for non-opioid pain medications, weak opioids, and strong opioids between 2006 and 2013
Non-opioids 2006 2013 % Diff 06-13
Number of personsa: 455'845 501'996 10
Age: median (IQR) 47 (41) 48 (41)
Female: n (%) 265'135 (58.2) 288'289 (57.4)
Number of claims: n 1'342'454 1'657'420 23
Number of claims / person 2.94 3.3 12
Paracetamol: number of claims 512'762 639'716 25
Metamizole: number of claims 55'000 185'168 237
NSAIDb: number of claims 174'293 329'075 89
Coxibs: number of claims 22'809 39'743 74
Paracematol: claims / 100'000 40'211 53'062 32
Metamizole: claims / 100'000 4'018 13'729 242
NSAID + Coxibs claims / 100'000 15'634 31'995 105
NSAID claims / 100'000 1'049'968 2'354'922 124
Coxibs claims / 100'000 123'981 249'306 101
Ibuprofen: claims / 100'000 235 395 68
Paracetamol: 1000 mg / 100'000 1'116'931 2'717'129 143
Metamizole: 1000 mg / 100'000 61'074 501'196 721
Weak opioids 2006 2013 % Diff 06-13
Number of personsa 53'786 55'604 3
Age: median (IQR) 61 (29) 62 (30)
Female: n (%) 33'172 (62) 33'629 (60)
Number of claims#: n 160'517 167'278 4
Number of claims / person 2.98 3.01 1
Number of claims / 100'000 11'957 13'348 13
Total MED in mg 50'339 57'782 15
Total MED in mg/Person 936 1'039 11
Total MED in 1000 mg/ 100'000 3'768 4'655 24
Tramadol in MED 1000 mg/ 100'000 3'046 3'750 23
Codeine MED in 1000 mg/ 100'000 722 587 −19
Tapentadol MED in 1000 mg / 100'000 - 317 -
Strong opioids 2006 2013 % Diff 06-13
Number of personsa 16'744 28'509 70
Age: median (IQR) 66 (27) 69 (29)
Female: n (%) 10'297 (62) 17'570 (62)
Number of claims: n 64'839 137'458 112
Number of claims / person 3.87 4.82 25
Number of claims / 100'000 4'716 10'419 121
Total MED 1000 mg 146'151 294'320 101
Total MED in mg/Person 8'729 10'324 18
Total treatment days 1'199 2'274 90
Total treatment days/ person 72 80 11
Total MED in 1000 mg/ 100'000 11'011 23'854 117
Total treatment days / 100'000 89'903 180'371 101
Total MED / treatment day 121.9 129.4 6
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frequently in the cantons of Jura, Fribourg, Basel-Stadt,
Uri, and Schaffhausen.
Results in light of the literature
After the recall of the popular coxib rofecoxib in 2005,
an analysis of consumer data in Switzerland found an in-
crease in the use of all non-opioid and opioid pain medi-
cations between 2000 and 2010 [5]. In this time period,
the use of strong opioids increased in Switzerland by
100% [5]. The current study expands on these findings
showing a further increase in prescriptions for all pain
medications and in particular for metamizole, NSAIDs,
Coxibs, paracetamol, and strong opioids. Similar to our
study, an analysis of insurance claims data in Germany
found an increased use of weak and strong opioids [24].
The increase was most pronounced for non-cancer pain
conditions. A recently published population-based co-
hort study in Denmark linked legally prescribed opioids
to an increased risk of deaths related to short- and long-
term opioid use in patients with chronic non-cancer
pain [25]. Wide geographical variations were also found
in Germany for the use of metamizole [26]. One explan-
ation may be that the assessment of an increased risk for
agranulocytosis in metamizole users compared to other
pain medications found in observational studies [27] var-
ies. Missing safety data resulted in a ban in the USA and
other countries [28] while metamizole remains a popular
medication in other countries. A recent meta-analysis of
the adverse effects of metamizole found that its short-
term use in a hospital setting is safe [29]. However,
insufficient evidence on the safety of long-term treat-
ment is available [29].
Great effort was undertaken by the WHO to improve
pain control in the world [4, 30]. The main objective
was to identify and improve areas where pain manage-
ment was insufficient. To date, current guidelines aim at
early and aggressive pain treatment in different settings
[31]. The use of strong opioids is well supported for the
treatment of acute severe pain, for cancer pain, and for
symptom relief at the end of life [32]. Here, the main
concern is that patients living in certain areas are under-
served and pain control is poor. In Switzerland, where
compulsory health insurance secures access to health
care, variations are more likely related to patient or
physician preferences. The personal beliefs of patients
and physicians may lead to reduced prescription of opi-
oids in the treatment of cancer pain [33], for example.
In chronic non-cancer pain, the efficacy of strong
Table 2 Change in claims for non-opioid pain medications, weak opioids, and strong opioids between 2006 and 2013 (Continued)
Morphine: MED 1000 mg / 100'000 2'875 4'648 62
Oxycodone and comb: MED 1000 mg / 100'000 1'237 5'110 313
Fentanyl: MED 1000 mg / 100'000 3'588 6'851 91
Pethidine: MED 1000 mg / 100'000 33 39 18
Hydromorphone: MED 1000 mg / 100'000 548 730 33
Methadone: MED 1000 mg / 100'000 28 424 1414
Buprenorphine: MED 1000 mg / 100'000 2'699 6'049 124
Nalbuphine: MED 1000 mg / 100'000 2 2 0
Morphine: treatment days / 100'000 28'988 46'856 62
Oxycodone: treatment days / 100'000 10'994 45'422 313
Fentanyl: treatment days / 100'000 29'941 57'953 94
Pethidine: treatment days / 100'000 411 491 19
Hydromorphone: treatment days / 100'000 3'657 4'988 36
Methadone: treatment days / 100'000 373 5'645 1413
Buprenorphine: treatment days / 100'000 15'509 18'985 22
Nalbuphine: treatment days / 100'000 31 30 −3
Oral long acting: MED 1000 mg / 100'000 4'409 9'761 121
Oral short acting: MED 1000 mg / 100'000 142 865 509
Parenteral: MED 1000 mg / 100'000 168 328 95
Rectal: MED 1000 mg / 100'000 5 9 80
Sublingual: MED 1000 mg / 100'000 1'243 4'986 301
Transdermal: MED 1000 mg / 100'000 5'045 7'905 57
anumber of subjects that received reimbursement for one of the corresponding pain medications for a specific year
bclaims for all NSAID
MED morphine equivalent dose
Wertli et al. BMC Health Services Research  (2017) 17:167 Page 7 of 11
opioids is less well established and the risk for adverse
events may outweigh the benefits [32, 34]. In chronic
non-cancer pain it is unclear whether an increased use
of strong opioids results in a better pain control. It is
also unclear why in certain areas of Switzerland strong
opioids are infrequently used and in others its use has
recently increased by more than 200%.
In the past 20 years, a 14-fold increase in strong opioid
use in the US was associated with an increased risk of
unintentional opioid overdose [13–16]. In Europe, the
increase in the use of opioids was less pronounced and
the risk for opioid addiction is generally assumed to be
low [35]. However, in a Danish cohort study the long-
term use of strong opioids in chronic pain was
Fig. 2 Reimbursement of pain medications in Switzerland between 2006 and 2013. The bold line represents the mean per/100’000 persons,
dotted lines represent the areas (cantons) in Switzerland
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associated with an increased risk for death and higher
risks of injuries and toxicity/poisoning [25]. While in the
US most overdose-related deaths were related to oxy-
codone, hydrocodone, and alprazolam [36], in Europe an
increase of the illicit use of fentanyl was described and is
best documented in Estonia [37]. Also in other European
countries, the increased use of fentanyl has led to
overdose-related deaths [37].
In most European countries, no surveillance system
is in place that would detect an opioid overuse and
unintentional overdose [38, 39]. Therefore, it is un-
clear whether an increase in unintentional opioid
overdose or opioid misuse would be detected [40].
Similarly to other European countries, the increase in
the use of strong opioids in the Swiss population was
less pronounced than in the US. However, in certain areas,
the use of strong opioids was well above the average.
Explanatory factors and the potential risk for drug over-
dose are unclear.
Strengths and limitations
To date, this is the first comprehensive analysis of insur-
ance claims data examining the use of pain medication
in the Swiss population. Great care was taken to assure
the quality of the data extracted from the claims data-
base. There are limitations that need further discussion.
On the one hand analyses of health insurance databases
on pain medications may overestimate the use of drugs
as they are based on medications reimbursed. The effect-
ive quantity of medications used by patients may be
lower, if pills are not actually taken. On the other hand,
we have no information on medications sold over the
counter (paracetamol, NSAIDs) and cross-border pur-
chases. Therefore, the quantity of ingested non-opioid
pain medications might be underestimated. We also
were not able to discriminate between the use of drugs
for pain or fever control and could not discriminate be-
tween the short- and long-term use of pain medications.
We excluded opioids used within drug substitution pro-
grams. However, some medications including morphine,
buprenorphine and methadone are used for both, pain
treatment and opioid substitution. While we identified
all records where the corresponding unique outpatient
code was used, we cannot exclude that opioids were
used for opioid dependency “off-label”. Whether the in-
crease in the use of pain medication led to an increase
Fig. 3 Differences in the use of pain medications in the Swiss cantons in 2013. Graphical representation of the reimbursed claims per 100’000
persons stratified for sex, age, and canton. Copyright geodata Swiss Federal Statistical Office / swisstopo
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in chronic use of pain medication is plausible but needs
to be confirmed with future studies.
Implication for research
The current analysis demonstrated an increase in the
prescription of almost all pain medications. In particular,
for strong opioids, physicians vary in their likelihood of
prescribing by canton. Further research should explore
the differences in the use of pain medications, in par-
ticular of strong opioids in cancer and non-cancer
related diseases to reveal under- or overuse of particular
medications. Further studies should investigate the inci-
dence of the severe hematologic adverse effects caused
by metamizole. Metimazole is a medication frequently
used in the German speaking part of Switzerland.
Conclusion
The analysis of insurance claims data provides evidence
that the prescription rates for pain medications increased
in Switzerland within the last ten years, in particular for
metamizole and strong opioids. A further major finding
was that the prescription rates for metamizole, paraceta-
mol, and strong opioids varied substantially between
different areas in Switzerland.
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